Reentry Assist (R-Assist) (R-Assist)

April 2, 2026 updated by: Meaningful Measurement, Inc

Reentry-Assist App Development for Individuals With Addiction and Mental Illness

This project will aim to develop and pilot test, R-Assist, a mobile health application to support individuals with co-occurring substance use and mental health disorders (COD) in their recovery, who have recently released from a participating Massachusetts jail.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This Phase I project will develop and test an mHealth app called R-Assist among individuals with COD recently released from a Massachusetts jail. R-Assist will offer four core features, including linkages to community resources via the resource locator, on demand, tailored self-help materials, and self-management/organizational tools. The following two Aims will be tested: Aim 1. R-Assist software and content prototype development. The 4 R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) social determinants of health (SDOH) resource finder; and 4) a dashboard to track R-Assist engagement. Aim 2. A successive cohort study of the R-Assist prototype with participants who have recently left jail (N = 38). This will include three successive field focus group cohorts with 18 participants, followed by a small open pilot with 20 participants. This project's four milestones will be executed in preparation for a larger Phase II trial.

  • Milestone 1 (Months 1-5): R-Assist App Development and Interface Designs

    o No human subjects involvement

  • Milestone 2 (Months 6-7): Initial Evaluation/Refinement of R-Assist

    o To recruit N=18 individuals for this Milestone

  • Milestone 3 (Months 8-10): Open Pilot of R-Assist

    o To recruit recruit N=20 individuals for this Milestone

  • Milestone 4 (Months 11-12): Product Refinement Prior to Phase II and Dissemination o No human subjects involvement

Study Type

Interventional

Enrollment (Estimated)

38

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Massachusetts
      • Worcester, Massachusetts, United States, 01605
        • University of Massachusetts Chan Medical School

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Have been released from the participating jail within the past 150 days
  • Own a smartphone (Android or iOS; 90% met this criterion in our prior studies)
  • Have COD: any substance use disorder (we will allow poly-substance use disorders) and a co-occurring mental health disorder (depression, anxiety, trauma related disorders, bipolar, and/or schizophrenia)
  • Consent to R-Assist app use observation and e-tracking
  • Consent to audio recording during interviews and focus groups.

Exclusion Criteria:

  • Acutely suicidal, homicidal, or psychotic
  • Unable to provide informed consent
  • Individuals released with monitoring devices or individuals involved in drug treatment courts

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: R-Assist
Participants who have recently released from jail will engage with the R-assist app for up to 1.5 months
Behavioral: reentry assistance mobile health app
R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session MISSION-CJ self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) SDOH resource finder; and 4) a dashboard to track R-Assist engagement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
App usage
Time Frame: From enrollment for 1.5 months during the open pilot
Total time engaged in app will be tracked daily during open pilot period. Additionally, engagement and time with each feature will be tracked
From enrollment for 1.5 months during the open pilot
System Usability Scale (SUS)
Time Frame: From enrollment for 1.5 months during the open pilot
Overall score will be computed, indicating overall usability Score ranges from 0-100 (0-64=not acceptable, 65-84=acceptable, and 85, 100=excellent.
From enrollment for 1.5 months during the open pilot
Mobile Application Rating Scale (MARS)
Time Frame: From enrollment for 1.5 months during the open pilot
Overall score will be computed, indicating overall acceptability, as well as score for each of the four dimensions. The rating scale assesses app quality on four dimensions (1. Engagement, 2. Functionality, 3. Aesthetics, and 4. Information). All items are rated on 5-point scale from "1=inadequate" to "5=excellent"
From enrollment for 1.5 months during the open pilot
Composite International Diagnostic Instrument for DSM-IV: Social determinants of health (SDOH) linkages
Time Frame: From enrollment for 1.5 months during the open pilot
SDOH needs (e.g., housing instability, food insecurity, NA/AA/ other recovery linkages) will be assessed and the App will track all referrals and SDOH linkages made. Percent of linkages made to needed SDOH services will be examined.
From enrollment for 1.5 months during the open pilot
Composite International Diagnostic Instrument for DSM-IV: Substance Use Disorder
Time Frame: From enrollment for 1.5 months during the open pilot
Substance use disorder symptoms will be tracked daily during the open pilot period.
From enrollment for 1.5 months during the open pilot
Composite International Diagnostic Instrument for DSM-IV: Mental Health
Time Frame: From enrollment for 1.5 months during the open pilot
Mental health symptoms will be tracked daily during the open pilot period.
From enrollment for 1.5 months during the open pilot

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Meaningful Measurement, Inc

Collaborators

National Institute on Drug Abuse (NIDA)
University of Massachusetts, Worcester

Investigators

  • Principal Investigator: David Smelson, PsyD, University of Massachusetts Chan Medical School
  • Principal Investigator: Donna Surges Tatum, PhD, Meaningful Measurement, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2025

Primary Completion (Actual)

March 31, 2026

Study Completion (Estimated)

April 30, 2026

Study Registration Dates

First Submitted

May 12, 2025

First Submitted That Met QC Criteria

May 12, 2025

First Posted (Actual)

May 20, 2025

Study Record Updates

Last Update Posted (Actual)

April 3, 2026

Last Update Submitted That Met QC Criteria

April 2, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00001884
  • R41DA061403 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Health Disorder

Clinical Trials on reentry assistance mobile health app

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe